Substituted aminobutyric derivatives as neprilysin inhibitors
US-2015174089-A1 · Jun 25, 2015 · US
(2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxmethyl-2-methylpentanoic acid
US9670143B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9670143-B2 |
| Application number | US-201615229398-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 5, 2016 |
| Priority date | Feb 11, 2015 |
| Publication date | Jun 6, 2017 |
| Grant date | Jun 6, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
In one aspect, the invention relates to a compound of the structure: or a pharmaceutically acceptable salt thereof, and a crystalline form of this compound, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this compound; methods of using this compound; and processes for preparing this compound.
First claim
Opening claim text (preview).
What is claimed is: 1. A calcium crystalline form of the compound: wherein the calcium crystalline form is characterized by a powder X-ray diffraction pattern having two or more diffraction peaks at 2θ values selected from 3.98±0.2, 5.00±0.2, 7.18±0.2, 7.38±0.2, 7.97±0.2, 8.87±0.2, and 10.91±0.2 and by a diffrential scanning calorimetry profile which shows a maximum in endothermic heat flow at a temperature in the range of about 237° C. and about 241° C. 2. A calcium crystalline form of the compound: wherein the calcium crystalline form is characterized by a powder X-ray diffraction pattern in which the peak positions are substantially in accordance with the peak positions of the pattern shown in FIG. 1 and by a differential scanning calorimetry profile substantially in accordance with that shown in FIG. 2 .
Assignees
Inventors
Classifications
Antihypertensives · CPC title
Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title
Drugs for disorders of the cardiovascular system · CPC title
of the kidneys · CPC title
- A61K9/0019Primary
Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9670143B2 cover?
- In one aspect, the invention relates to a compound of the structure: or a pharmaceutically acceptable salt thereof, and a crystalline form of this compound, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this compound; methods of using this compound; and processes for preparing this compound.
- Who is the assignee on this patent?
- Theravance Biopharma R&D Ip Llc
- What technology area does this patent fall under?
- Primary CPC classification A61K9/0019. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 06 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).